Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

Every year, my colleagues and I put together a list of what we think are the top 10 breakthrough technologies of that year.

Gilead has reported results for a once-yearly intramuscular injection that show blood concentrations of lenacapavir exceeded ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

UCSF researchers are the first to confirm that this approach is effective for the patients who need it most. Patients who ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.

Nearly half of all new cases in 2022 were in the South. "The frustrating part is we have the tools now to stop it." ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

HIV is currently the only disease carrying a felony charge if someone knowingly transmits it to another person. The Senate ...

A patient told MassLive she was horrified to receive a phone call from her surgeon post-operation saying she should be tested for bloodborne pathogens.

Prominent gaps in pediatric and adolescent HIV care translate into priorities that need to be addressed for optimizing care ...